Skip to main content
    V

    Viemed Healthcare Inc (VMD)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $9.07
    -0.08 (-0.87%)

    Market Cap: $346.72M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Viemed Healthcare Inc (VMD) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Viemed Healthcare (VMD) has a market cap of $346.72M and an enterprise value of $342.07M. Revenue grew 21.81% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 1.34% below the market cap, as cash exceeds debt.

    Market Cap$346.72M
    Enterprise Value$342.07M
    Latest price (Nov 17, 2026)$9.07

    Key Dates

    The next earnings report is expected on Mar 2, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 2, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 0.38% in the quarter ended Sep 30, 2026 and shrank 0.99% a year over 2 years.

    Shares Outstanding38.10M
    Shares Change (YoY)-1.39%
    Shares Change (QoQ)-0.38%
    Share Count Growth (2Y CAGR)-0.99%

    Valuation Ratios

    Sales and book value multiples are 1.1x and 2.3x. Its year-end P/E ranged from 9.9x to 50.4x from 2018 to 2025.

    P/E Ratio23.9x
    Forward P/E21.7x
    P/S Ratio1.1x
    Forward P/S1.1x
    P/B Ratio2.3x
    P/TBV Ratio3.8x
    P/FCF Ratio16.2x
    P/OCF Ratio6.4x
    PEG Ratio0.9

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 6.2x EBITDA and 15.9x free cash flow.

    EV / Earnings21.2x
    EV / Sales1.1x
    EV / EBITDA6.2x
    EV / EBIT14.1x
    EV / FCF15.9x

    Price Statistics

    The stock is up 41.94% over 52 weeks and trades 2.37% below its 50-day average.

    Beta (1Y)0.46
    52-Week Change+41.94%
    1-Month Change-5.42%
    3-Month Change+1.45%
    6-Month Change-5.62%
    5-Year Change+68.76%
    Total Return (1Y)+41.94%
    Total Return (3Y CAGR)+5.75%
    Total Return (5Y CAGR)+10.25%
    Return vs SPY (1Y)+32.18%
    Max Drawdown (1Y)-30.49%
    Max Drawdown (3Y)-40.64%
    Sharpe Ratio (1Y)0.88
    Correlation with SPY (1Y)0.15
    50-Day Average$9.29
    200-Day Average$9.67
    52-Week Range$6.18 to $12.61
    RSI (14 Days)43.4
    Average Volume (20 Days)205.98K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.25x current liabilities, and total debt is 0.03x shareholder equity.

    Current Ratio1.25x
    Quick Ratio1.16x
    Debt / Equity0.03x
    Debt / EBITDA0.09x
    Debt / FCF0.23x

    Returns and Efficiency

    Return on invested capital is 11.10% over the last 12 months, against a 5-year average of 8.67%.

    Return on Equity (ROE)10.77%
    Return on Assets (ROA)7.79%
    Return on Invested Capital (ROIC)11.10%
    Return on Capital Employed (ROCE)15.17%
    ROE (5Y Average)8.91%
    ROA (5Y Average)6.77%
    ROIC (5Y Average)8.67%
    Asset Turnover1.51x
    Inventory Turnover26.92x
    Receivables Turnover9.25x
    Cash Conversion Cycle23 days

    Taxes

    Income tax took 29.20% of pretax income over the last 12 months.

    Income Tax (TTM)$6.67M
    Effective Tax Rate29.20%

    Scores

    VMD has an Altman Z-Score of 6.44, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score6.44
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $310.37M over the last 12 months.

    Revenue$310.37M
    Revenue Growth (YoY)+21.81%
    Gross Profit$178.17M
    Operating Income$24.09M
    Pretax Income$22.83M
    Net Income$16.17M
    EBITDA$55.05M
    EBIT$24.31M
    Reported EPS (TTM)$0.38

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 72.29% of the $207.63M in total assets.

    Cash and Equivalents$9.68M
    Total Debt$5.02M
    Net Cash$4.66M
    Net Cash Per Share$0.12
    Working Capital$11.97M
    Shareholder Equity$150.09M
    Book Value Per Share$3.94
    Tangible Book Value$90.06M
    Tangible Book Per Share$2.36
    Total Assets$207.63M
    Total Liabilities$55.65M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $32.52M of capital spending, operating cash flow left $21.38M of free cash flow.

    Operating Cash Flow$53.90M
    Capital Expenditures$32.52M
    Free Cash Flow$21.38M
    FCF Per Share$0.56
    Depreciation and Amortization$30.73M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 7.76%, against a 5-year average of 8.03%.

    Gross Margin57.41%
    Operating Margin7.76%
    Pretax Margin7.36%
    Net Margin5.21%
    EBITDA Margin17.74%
    EBIT Margin7.83%
    FCF Margin6.89%
    Gross Margin (5Y Average)60.45%
    Operating Margin (5Y Average)8.03%
    Net Margin (5Y Average)5.73%

    Growth

    Revenue grew 24.87% a year over 3 years, and EPS 35.11% a year.

    Revenue Growth (3Y CAGR)+24.87%
    Revenue Growth (5Y CAGR)+15.53%
    EPS Growth (3Y CAGR)+35.11%
    EPS Growth (5Y CAGR)-13.86%
    FCF Growth (3Y CAGR)+36.33%
    FCF Growth (5Y CAGR)-11.57%
    Operating Income Growth (3Y CAGR)+40.63%
    Book Value Per Share Growth (2Y CAGR)+11.79%
    Tangible Book Per Share Growth (2Y CAGR)-1.07%

    Revenue and profit by year

    Dividends and Yields

    VMD does not pay a dividend. Its free cash flow yield is 6.19%.

    Earnings Yield4.18%
    FCF Yield6.19%
    Buyback Yield2.24%
    Shareholder Yield2.39%

    Peer Position

    Against 6 similar companies, VMD has the 4th highest P/E.

    P/E Ratio23.9x vs 24.2x median
    P/S Ratio1.1x vs 1.8x median
    ROIC11.10% vs -9.98% median
    Revenue Growth (Trailing 4 Quarters, YoY)+21.81% vs +9.94% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 13.71% and EPS growth at 18.17% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+13.71%
    EPS Growth Forecast (2Y CAGR)+18.17%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About VMD

    What is VMD's market cap?

    Viemed Healthcare has a market cap of $346.72M. Its enterprise value, which adds debt and subtracts cash, is $342.07M.

    What is VMD's P/E ratio?

    Viemed Healthcare has a trailing P/E ratio of 23.9x and a forward P/E of 21.7x.

    How many shares of VMD are outstanding?

    Viemed Healthcare has 38.10M shares outstanding. The count is down 1.39% from a year earlier.

    Does VMD pay a dividend?

    No. Viemed Healthcare does not pay a dividend.

    How much debt does VMD have?

    Viemed Healthcare has $5.02M of total debt and $9.68M of cash and equivalents, a net cash position of $4.66M.